The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
231
Change from Baseline in MG-ADL Score for Antibody-positive Participants
Time frame: Baseline to Week 12
Change from Baseline in Quantitative Myasthenia Gravis (QMG) Score for Antibody-positive Participants
Time frame: Baseline to Week 12
Percentage of Antibody-positive Participants Achieving MG-ADL Score of 0 or 1
Time frame: Week 12
Percentage of Antibody-positive Participants with ≥50% Improvement in MG-ADL Score
Time frame: Baseline to Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
* Dose 1 SC QW for 14 weeks (Period 2) * Dose 1 SC QW for 52 weeks (Period 3)
Site Number - 1041
Mobile, Alabama, United States
RECRUITINGSite Number - 1017
Phoenix, Arizona, United States
RECRUITINGSite Number - 1025
Scottsdale, Arizona, United States
RECRUITINGSite Number - 1042
Tucson, Arizona, United States
RECRUITINGSite Number - 1010
Carlsbad, California, United States
RECRUITINGSite Number - 1028
Irvine, California, United States
RECRUITINGSite Number - 1023
Los Angeles, California, United States
RECRUITINGSite Number - 1029
Rancho Mirage, California, United States
RECRUITINGSite Number - 1004
San Francisco, California, United States
RECRUITINGSite Number - 1027
Fort Collins, Colorado, United States
RECRUITING...and 48 more locations